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(PBSC) donation does not require hospitalization and is gen-
erally assumed to be less physically demanding for the donor. 
However, application of mobilizing agents is stringently re-
quired for successful HSC mobilization. The standard sub-
stance, which is almost exclusively used in healthy donors 
worldwide, is recombinant human granulocyte colony-stimu-
lating factor (rhG-CSF). Two preparations – filgrastim and 
lenograstim – are available and have been approved for PBSC 
mobilization for about 15 years in Germany. Currently, more 
than 20,000 healthy donors worldwide receive rhG-CSF for 
PBSC mobilization every year [7]. At the Dresden University 
Hospital, PBSC collections have been performed since 1996. 
In the two collection facilities associated with the university 
hospital, 8,290 allogeneic PBSC collections from 8,005 donors 
(i.e. 285 second collections) have been documented in a data-
base up until May 2012. This paper presents the data of our 
own group, and summarizes the current knowledge regarding 
the short- and long-term effects of G-CSF treatment in 
healthy stem cell donors.
Donor Eligibility
HSC donors should generally fulfill the requirements of 
the German Guidelines of Hemotherapy for apheresis donors 
[8]. Donor evaluation comprises primarily the following ele-
ments: i) detailed medical history, supported by a standard-
ized questionnaire; ii) physical assessment with special consid-
eration of peripheral veins; iii) electrocardiogram (ECG) at 
rest; iv) ultrasound examination of the upper abdomen with 
measurement of spleen diameter; and v) laboratory examina-
tions including complete blood count with differential, clinical 
chemistry (liver enzymes, electrolytes, metabolic parameters, 
serum protein electrophoresis), urinalysis, infectious disease 
markers (hepatitis A/B/C, HIV, human T-cell lymphotropic 
virus type (HTLV) I/II, syphilis, toxoplasmosis, Epstein-Barr 
virus (EBV), cytomegalovirus (CMV)), ABO, rhesus (Rh) 
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Summary
Mobilization of peripheral blood stem cells (PBSC) in 
healthy volunteers with granulocyte colony-stimulating 
factor (G-CSF) is currently carried out at many institu-
tions worldwide. This report presents the experience of 
the Dresden center regarding donor evaluation and mo-
bilization schedule. Data regarding efficacy, short- and 
long-term safety of G-CSF treatment gained from 8290 
PBSC collections in healthy donors are outlined. These 
results are discussed against the background of the 
available evidence from the literature. Although estab-
lished as a standard procedure, G-CSF application to all-
ogeneic donors will always be a very delicate procedure 
and requires the utmost commitment of all staff involved 
to ensure maximum donor safety.
Introduction
Allogeneic transplantation of hematopoietic blood stem 
cells (HSC) became a routine clinical procedure during the 
1990s. It is a promising treatment option for patients with life-
threatening diseases of the hematopoietic and immune sys-
tems [1, 2]. Initially, HSC were obtained from bone marrow 
(BM) only [3]. In the mid-1990s, mobilization of HSC from 
BM into peripheral blood was also applied in healthy donors 
[4–6]. These cells could easily be collected with common 
blood cell separators. The method evolved very quickly into 
an alternative to BM collection, and soon became the most 
widely used way to harvest HSC from healthy allogeneic do-
nors. In contrast to BM collection, peripheral blood stem cell 
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number of colony-forming units (colony-forming units granu-
locyte/macrophage (CFU-GM), burst-forming units-erythro-
cyte (BFU-E)) reached their maximum. Studies with even 
higher G-CSF doses [20] indicate that this peak may occur 1 
day earlier. On the other hand, there is some evidence that 
G-CSF doses higher than 10 g/kg are associated with more 
frequent side effects [21, 22]. Our group used a median dose 
of 7.5 g/kg lenograstim (6.8–8.5 g/kg) during a period of 
4.5–5.5 days. In this protocol, the peripheral CD34+ count on 
day 5 of G-CSF application varied between 6 and 285/ l in 
3,928 unrelated PBSC donors [23] (fig. 1). The median total 
yield from the first leukapheresis was 5.88 (0.16–27.39) × 108 
CD34+ cells (fig. 2). A single leukapheresis was sufficient to 
collect the CD34+ cell dose required in 3,072 donors (78.2%). 
typing, pregnancy test in women with childbearing age (urine 
or serum). Abnormal findings have to be further evaluated in-
dividually. Infectious disease markers are mainly analyzed for 
the safety of the recipient, while the other tests are also per-
formed to facilitate donor safety. Exclusion of hematologic 
diseases is of specific importance for the safety of donor and 
recipient. During G-CSF application, occult leukemic clones 
could be stimulated [9]; furthermore, transmission of malig-
nant clones from donor to recipient can occur during trans-
plantation [10]. At least 11 cases of transmission of hemato-
logic malignancies from healthy adult donors to recipients of 
blood stem cell transplants have been published so far [11]. 
Some investigators recommend BM evaluation in related 
stem cell donors over the age of 55 [12], but the common 
standard of donor evaluation remains complete blood count 
with automatic differential. Because malignancies of other 
organ systems can also be transferred with hematopoietic 
stem cell products, donors with a history of malignancy are 
generally excluded from PBSC donation. Active autoimmune 
diseases are also an exclusion criterion in most cases. Older 
sibling donors require special attention because many dis-
eases, e.g. of the cardiovascular system, occur with higher fre-
quency and can increase the risk of complication of PBSC 
mobilization and collection [13]. Additional investigations 
(exercise ECG, echocardiography) and subspecialty consulta-
tions are often required in these donors [13]. Application of 
G-CSF to pediatric donors, not able to consent autonomously, 
is legally prohibited in Germany. Donor evaluation is the re-
sponsibility of a separate team of physicians not involved in 
the care of the recipient to avoid conflicts of interest.
G-CSF Dosing and Factors Affecting Mobilization 
Efficacy
The dose-response relationship of G-CSF has been studied 
by many different groups (see overview in [14]). A wide range 
of dosages (3–20 g/kg) has been applied to healthy PBSC 
 donors (table 1). Even at a G-CSF dose as low as 3 g/kg, 
CD34+ cells could be detected, but the amount was not suffi-
cient for clinical application [15]. Due to the large interindi-
vidual variation of mobilization efficacy, the number of do-
nors included in some of these studies is limited. Furthermore, 
it has to be considered that CD34 measurement was not well 
standardized when those reports were published. There also 
have been large variations in the leukapheresis procedures. 
Altogether, only 3 investigators could detect significant differ-
ences of PBSC mobilization at different G-CSF-dosages [16, 
17]. Sekhsaria et al. [18] could only find significant differences 
in individual donors who consecutively received both G-CSF 
doses (5 and 10 g/kg). The two prospective studies by Stron-
cek et al. [15] and Grigg et al. [19] revealed a peak of periph-
eral CD34 values after 4–6 days of G-CSF application at a 
maximum daily dose of 10 g/kg. At the same time, the 
Fig. 1. Concentration of CD34+ cells in peripheral blood on day 5 of G-
CSF-application, prior to the first leukapheresis (counts per l).
Fig. 2. Yield of CD34+ cells in the first leukapheresis (×108).
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[35–37]. CD34+ counts after the second G-CSF cycle in our 
donor population were reduced by about 10% compared with 
values after the first mobilization, but were all still in the same 
order of magnitude. First evidence of a genetic background 
determining stem cell mobilization was provided by Benboub-
ker et al. [38] who reported an association between the 
CXCL12–3 A allele and a better mobilization result in healthy 
stem cell donors. This result could be confirmed by Bogunia-
Kubik et al. [39] and Ben et al. [40]. Martin-Antonio et al. [41] 
reported the same finding and observed associations between 
mobilization ability and even more polymorphisms, including 
VCAM-1 und CD44. An analysis of our group could not show 
a significant association of the CXCL12–3 A allele with more 
efficient stem cell mobilization in 463 unrelated donors 
(Schmidt J, Bornhäuser M et al., submitted).
Short-Term Side Effects of G-CSF Administration
The usual complaints, reported by a large proportion of 
healthy donors during G-CSF administration, are bone pain, 
headache and flu-like symptoms like malaise, nausea, subfe-
brile body temperature and night sweats [13, 23, 42]. Further-
more, muscle pain, insomnia, anorexia, and vomiting can 
occur less often. Frequency and severity of the most common 
side effects were described in two recent studies in unrelated 
donors [23, 43] (fig. 3). Both groups found a frequency of skel-
etal pain of about 90% of the donors, but the intensity was 
mild or moderate in the majority of cases. The incidence of 
flu-like symptoms differed between the reports, obviously due 
to differences in data collection. The study of Pulsipher et al. 
[43] represents the most comprehensive and detailed survey 
about G-CSF-induced side effects reported so far, and is the 
first to prospectively compare the experiences of unrelated 
BM and PBSC donors [43]. The incidence of pain was compa-
rable in both groups, but PBSC donors had a significantly 
faster and higher probability of complete recovery from their 
complaints than BM donors.
In the majority of donors (99.5%), enough CD34+ cells could 
be collected in 1 or 2 aphereses. Only in 0.45% of the donors 
(n = 18), the CD34 yield was less than 2 × 106/kg recipient 
body weight in 2 leukaphereses, carrying a high risk of graft 
failure in the recipients [23]. Donors not mobilizing adequate 
numbers of CD34+ cells after G-CSF administration are 
called ‘poor mobilizers’ and can be found in proportions be-
tween 2 and 5% in the literature [24–27]. In related donors, 
the fraction with poor response to G-CSF application was 2% 
in our experience. The remarkable variability in the response 
to G-CSF creates significant uncertainty for allogeneic trans-
plantation programs. It would be valuable to prospectively 
identify the donors with poor mobilization in order to target 
them selectively with different priming strategies [28]. Since 
the 1990s, many groups have investigated the influence of sev-
eral factors on the mobilization ability of healthy donors. 
Table 2 shows the key data published by other groups [24, 
29–34] and the results of our study. As compared to the litera-
ture, we analyzed the largest group of donors treated with a 
uniform G-CSF dosage. Several analyses, including our own, 
revealed a better mobilization in male than in female donors. 
Higher body weight or higher body mass index of the donors 
enhanced mobilization efficacy in all studies investigating this 
parameter. Platelet count at baseline also significantly influ-
enced PBSC mobilization in some studies. Data of most 
groups showed no or only a minor impact of donor age on 
mobilization efficacy. This finding is clinically relevant with 
regard to an increasingly older patient population with sibling 
donors of comparable age. Another important result is the ad-
vantage of divided G-CSF doses over single daily doses. Sum-
marizing these data, a reliable prediction of CD34+ cell mobi-
lization in an individual donor cannot be made on the basis of 
demographic parameters or blood counts at baseline. The mo-
bilization ability of an individual donor is very likely related 
to genetic polymorphisms. This assumption is supported by 
the results of second PBSC mobilizations in the same donors. 
All studies published including our own data showed a fair 
consistency between the first and second mobilization result 
Fig. 3. Side effects of G-CSF (% of all dona-
tions, n = 4,050) [23].
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complications of G-CSF treatment. A few cases of acute res-
piratory distress syndrome (ARDS) after G-CSF application 
have been reported in healthy donors, the pathogenesis re-
mains hypothetical [55–57]. In our study, we observed pulmo-
nary infiltrates during or shortly after G-CSF treatment in 3 
donors, but all suffered from concomitant bacterial or viral in-
fections [58]. 
Another potential hazard of stem cell mobilization with 
G-CSF might be a transient state of hypercoagulability that 
could give rise to thrombotic complications, especially in older 
sibling donors [59–61]. There are some reports of increased 
plasma markers of endothelial activation and activated plas-
matic coagulation, but findings are partially conflicting [62]. 
Vascular events among healthy stem cell donors during G-CSF 
treatment are rarely reported [54]. Among 8,290 healthy do-
nors, we observed one young man (age 24 years) with deep 
vein thrombosis 1 day after stem cell collection and one 
63-year-old female sibling donor with a cerebral insult 2 weeks 
after PBSC donation. This number does not imply a clinically 
significant thrombotic risk in healthy PBSC donors. 
Results from Long-Term Follow-Up after G-CSF  
Administration
While follow-up of unrelated PBSC donors is routinely 
conducted by the registries, there is no ongoing large scale in-
ternational registry prospectively monitoring related donors 
[13]. Because of that, available data might be biased by a sig-
nificant number of unreported cases. In our study, the propor-
tion of donors participating in the follow-up investigations 4 
weeks after donation was 67%, but was reduced to 38.1% 
after 5 years. Altogether, our follow-up data included 16,242.3 
donor years. The vast majority of PBSC donors consider their 
general condition excellent or good throughout the observa-
tion period (fig. 4).
Reports on the course of blood counts after PBSC collec-
tion are partly controversial. In our donor cohort, leukocyte 
Our own results and the data of Pulsipher et al. [43] re-
vealed a higher intensity of pain in donors who were over-
weight or obese. Pain was also more frequently reported by 
female donors. Surprisingly, both studies recorded a lower 
probability of pain in older donors. In our program, related 
donors had a lower incidence and severity of pain, possibly 
due to the different psychological situation of this subgroup. 
Besides, the median age of siblings was 48 years compared to 
a median age of 34 years in unrelated donors, which might 
partially account for the lower incidence of pain in the related 
donor population. From a clinical point of view, all of the typ-
ical G-CSF-associated side effects normally respond quickly 
to non-steroid analgesics like acetaminophen or ibuprofen. 
With such medication, substantial impairment of the donor’s 
general condition can generally be avoided [13]. 
Laboratory findings after G-CSF treatment are character-
ized by a typical leukocytosis, but also a mild decrease in 
platelet count and potassium concentration and an increase in 
uric acid, alkaline phosphatase, transaminases and lactate de-
hydrogenase levels [44]. 
G-CSF administration causes a slight spleen enlargement 
in the majority of healthy donors [45–47], which normally re-
solves within a few weeks. The magnitude of splenomegaly 
might be related to the daily dose and duration of G-CSF 
treatment [47]. An uncommon but potentially life-threatening 
complication is splenic rupture. There are at least 6 cases of 
this dreaded event in healthy donors after G-CSF application 
reported in the literature [48–53]. In these donors, the daily 
G-CSF dosage was between 10–20 g/kg, in 3 cases mobiliza-
tion was continued until day 6. Tigue et al. [54] assume an in-
cidence between 1:5,000 and 1:10,000 for splenic rupture in 
healthy stem cell donors. Donors should be counseled to 
avoid contact sports and other risks for abdominal trauma 
during the time of G-CSF administration and about 1 week 
thereafter. In donors with preexisting splenomegaly, the 
G-CSF dose might be preventively reduced. 
Pulmonary events such as interstitial pneumonitis, pulmo-
nary infiltrates, and lung fibrosis are other rare but serious 
Fig. 4. General health status of donors during 
the follow-up period. Estimates of overall con-
dition (percentage of all donors responding to 
the follow-up survey). Estimates are self-assess-
ments of the donors.
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sides these clearly demonstrable effects on hematologic pa-
rameters, a clinical impact, e.g., an increased susceptibility to 
infections after PBSC donation, has never been reported in 
the literature. Altogether, it can be concluded that hemato-
logic effects of G-CSF treatment are self-limiting and clini-
cally acceptable.
The question whether G-CSF exposure of healthy donors 
could increase the risk of later development of hematologic 
(especially myeloid) malignancies has been debated since the 
very beginning of allogeneic PBSC mobilization. During the 
last years, follow-up data from stem cell donor registries and 
several collection centers have been reported. The results of 
our follow-up study are shown in table 3. Malignancies have 
been reported in 28 donors (0, 34%) during follow-up, 8 of 
these being hematologic malignancies. Referring to the stand-
ardized incidence ratio and the respective confidence interval, 
the incidences of acute myeloid leukemia (AML) and Hodg-
kin’s disease in the cohort of donors investigated turned out 
to be significantly different from the natural incidence in the 
German population. The incidences of the other malignant 
diseases did not differ significantly from the age- and gender-
adjusted German population. Some groups did not observe 
any hematologic malignancies in PBSC donors [64, 67–69]. 
Some cases of AML have been published in related donors [9, 
70]. The NMDP reported data of 4,015 unrelated donors who 
were monitored more than 1 year after their PBSC donation 
(9,785 donor years) with no cases of leukemia or lymphoma 
[71]. A retrospective follow-up survey of the German Bone 
Marrow Donor Registry (DKMS) evaluated all PBSC and 
BM donors donating through January 2009 [72]. This study 
counts were significantly lower 4 weeks after PBSC collection 
as compared to baseline. During further follow-up, white 
blood cells gradually recovered. Lymphocyte counts returned 
to baseline values between 1 and 2 years after donation, but 
neutrophile counts remained slightly but significantly below 
the initial values throughout the follow-up period. With the 
exception of some [63], this effect was reported by the major-
ity of the more recent studies [64, 65]. In the latest publica-
tion, the NMDP survey, Pulsipher et al. [43] report also on a 
delayed normalization of leucocyte counts, resolving by year 
3, the last point of follow-up. In this study, platelet counts and 
hemoglobin levels were slightly decreased from baseline after 
both BM and PBSC donation through year 3. This finding was 
not observed in our study and in the other previous reports 
[64, 65]. The mechanisms underlying these effects remain un-
clear. As Anderlini et al. [66] already stated in 1996, the rela-
tive contributions of mobilization and leukapheresis have not 
yet been elucidated. To analyze this phenomenon in more de-
tail, we separately evaluated the hematologic recovery of 
‘poor mobilizers’ (donating less than 2 × 106 CD34+ cells/kg 
recipient weight in the first apheresis). These donors are char-
acterized by lower baseline values, but also by a remarkably 
delayed normalization of leukocyte counts (fig. 5). Between 
years 2 and 5, white blood cells were still 9% lower than the 
baseline value. These observations cannot be easily explained. 
Conceivably, there might be distinct differences in the prolif-
eration dynamics of the individual stem cell pools. A better 
understanding of the underlying mechanisms would be highly 
desirable and would help make a more informed decision 
about second donation requests from individual donors. Be-
Fig. 5. Donor white blood cell (WBC) counts 
in poor mobilizers (less than 2 × 106 CD34+ 
cells/kg recipient weight in first apheresis) com-
pared with the other donors at baseline and at 
postdonation follow-ups.
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cells, and DNA destabilization. These findings have raised 
much concern regarding the safety of allogeneic PBSC do-
nors; however, some other studies published by the NMDP 
and other groups [75–78] could not confirm these data. Never-
theless, this issue has to be investigated carefully and thor-
oughly in future studies. 
Conclusion
Mobilization of PBSC with G-CSF and leukapheresis has 
become a well-established procedure worldwide and is the 
predominating technique for the procurement of allogeneic 
hematopoietic stem cell transplants. Although G-CSF has a 
clear dose response relationship, the wide variety of mobiliza-
tion efficacy remains a major challenge in the management of 
the individual donor. Parameters that allow prediction of mo-
bilization potential would therefore be highly desirable. 
Short-term side effects as well as hematologic changes after 
G-CSF application are generally tolerable and do not pose se-
rious risks for healthy donors. Long-term follow-up remains 
an ongoing endeavor and should be carried out with the most 
appropriate statistical instruments and the utmost accuracy to 
guarantee the safety of related and unrelated voluntary PBSC 
donors.
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had a response rate of 81.3% of the donors and documented 
55,229 observation years, of these 30,777 in PBSC donors. 
This analysis revealed no clustering of leukemia or lympho-
mas; however, a significantly increased incidence of malignant 
melanoma was shown in BM donors. Halter et al. [42] pre-
sented a retrospective multicenter EBMT study covering 
51,024 first allogeneic hematopoietic stem cell donations 
(27,770 BM and 23,254 PBSC) [42]. In this survey, 20 hemato-
logic malignancies were reported (8 in bone marrow donors, 
12 in PBSC donors). The incidences in both groups were 
below the age-adjusted values of the control population and 
there have been no statistically significant differences be-
tween BM and PBSC donors. However, the authors state that 
there might be some underreporting because of the retrospec-
tive and heterogenic character of their data. Added together, 
there is still no sufficient evidence to definitely prove or dis-
prove the hypothesis that G-CSF administration affects the 
risk of leukemia in healthy donors. According to calculations 
by Schmidt et al. [72], at least 90,000 donor years would be 
required to detect a duplication of leukemia risk. This figure 
illustrates the enormous logistical challenges facing sophisti-
cated donor follow-up programs.
The major question, whether G-CSF promotes leukemo-
genesis via genetic or epigenetic alterations, cannot currently 
be answered. Mutations in the G-CSF receptor have been 
identified in patients with severe congenital neutropenia and 
have been shown to be characteristic for this disease [73]. 
These receptors provoke an excessive cell proliferation after 
stimulation with G-CSF and can thereby contribute to the de-
velopment of leukemia. From in vitro investigations, Nagler 
et al. [74] reported epigenetic and genetic alterations in lym-
phocytes, changes in gene expression patterns in mononuclear 
Table 3. Malignancies during the follow-up period after PBSC donation
Interval after PBSC donation Donors, n Location Age, years Crude rate SIR 95% CI
1 month – 5 years 6 breast cancer 44–52 125.7  2.03 0.7–4.4
2–3 years 3 testicular carcinoma/seminoma 38–41  26.2  1.37 0.3–4.0
1; 5 years 2 cervical carcinoma 34; 43  41.9  3.77 0.5–13.0
2; 4 years 2 thyroid carcinoma 24;50  12.3  2.60 0.3–9.4
3 years 1 bronchial carcinoma 42   6.2  0.82 0.0–4.6
6 months 1 malignant melanoma 50   6.2  0.54 0.0–3.0
3 years 1 basal cell carcinoma 46   6.2  – –
4 years 1 rectal carcinoma 57   6.2  2.18 0.1–12.1
1 year 1 thymus carcinoid 34   6.2  – –
3 years 1 brain tumor 40   6.2  1.53 0.0–8.5
2–4 years 2 unknown 41–53  12.3  – –
1 month 1 chronic lymphatic leukemia 37   6.2 11.55 0.3–64.3
2; 7 years 2 acute myeloid leukemia 35;61  12.3 11.41 1.4–41.2a
7 years 1 chronic myeloid leukemia 45   6.2  7.93 0.2–44.2
1.5 years 1 acute lymphatic leukemia 27   6.2  8.40 0.2–46.8
6 months – 2 years 3 Hodgkin’s disease 28–40  18.5  6.17 1.3–18.0a
aStatistically significant.
SIR = Standardized incidence ratio; CI = confidence interval.
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